US 8293719
iRNA agents targeting VEGF
granted A61KA61K31/7088A61K31/712
Quick answer
US patent 8293719 (iRNA agents targeting VEGF) held by Alnylam Pharmaceuticals, Inc. expires Mon Oct 18 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue Oct 23 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 18 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 25
- CPC classes
- A61K, A61K31/7088, A61K31/712, A61K31/713, A61K47/02